Mylod%252525252525252525252520at

# Mylodat (Mylod) - *Note: Commonly refers to Mylon/Mylod (Loperamide hydrochloride variant or combination brands vary by region. Please confirm the specific active ingredient).* *This response assumes Loperamide Hydrochloride, as "Mylod" is a common trade name for this anti-motility agent in several international markets.* ## Overview Mylodat (Loperamide) is a synthetic piperidine derivative that acts as a peripheral mu-opioid receptor agonist in the intestinal wall. It inhibits peristalsis and prolongs transit time, resulting in decreased fecal volume and frequency. ## Primary Indications - Symptomatic control of acute non-specific diarrhea. - Management of chronic diarrhea associated with inflammatory bowel disease or short bowel syndrome. ## Adult Dosing - **Acute Diarrhea:** Initial 4 mg orally, followed by 2 mg after each unformed stool. - **Maximum Dose:** 16 mg/day. - **Chronic Diarrhea:** Starting dose 4–8 mg/day divided; titrate based on stool consistency. - **Maximum Dose:** 16 mg/day (unless directed by a specialist). ## Pediatric Dosing *Consult specific local protocols; dosing below is generalized guidance.* - **Children 2–5 years:** 1 mg orally 3 times daily (first day only). - **Children 6–8 years:** 2 mg twice daily (first day only). - **Children 9–12 years:** 2 mg 3 times daily (first day only). - **Maintenance:** Often 0.1 mg/kg given after each unformed stool, not exceeding the first-day dose. - **Note:** Generally not recommended for children under 2 years of age due to risk of paralytic ileus and respiratory depression. ## Dose Adjustments - **Hepatic Impairment:** Use with caution. Monitor closely for signs of CNS toxicity due to reduced first-pass metabolism. - **Renal Impairment:** No specific dose adjustment defined; drug undergoes minimal renal excretion. ## Contraindications - Hypersensitivity to loperamide. - Diarrhea associated with organisms that penetrate intestinal mucosa (e.g., *E. coli*, *Salmonella*, *Shigella*). - Pseudomembranous colitis (antibiotic-associated diarrhea). - Conditions where inhibition of peristalsis should be avoided (e.g., ulcerative colitis flare-up, abdominal distension, ileus). ## Adverse Effects - **Common:** Constipation, abdominal cramps, nausea, dizziness. - **Serious:** Toxic megacolon, paralytic ileus, cardiac arrhythmias (QT prolongation, Torsades de Pointes—typically only seen at supratherapeutic, extreme doses). ## Key Drug Interactions - **CYP3A4/2C8 Inhibitors (e.g., Ritonavir, Itraconazole, Ketoconazole):** Increase plasma concentrations of loperamide, significantly raising the risk of cardiac toxicity. - **Saquinavir:** Loperamide may decrease the absorption of saquinavir. - **CNS Depressants:** May potentiate sedation. ## Monitoring - Monitor frequency and consistency of stools. - Discontinue if no clinical improvement within 48 hours. - Assess for signs of abdominal distension or ileus, especially in pediatric or elderly populations. - Monitor for signs of cardiac toxicity (e.g., syncope, palpitations) if doses approach or exceed recommended limits. ## Clinical Pearls - **Hydration:** Loperamide does not hydrate the patient; always initiate oral rehydration therapy in cases of acute diarrhea. - **Abuse Potential:** High-dose loperamide is sometimes misused for opioid withdrawal management; clinicians should be vigilant of "loperamide abuse" in patients presenting with unexplained QT prolongation or syncope. - **Self-limiting:** If diarrhea is accompanied by high fever or systemic signs of toxicity, do not utilize loperamide. *** **Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and local drug availability before administration.